Background Complement factor B (CFB), a key component of the alternative complement pathway, has been implicated in tumor‐related inflammation; however, its causal role and therapeutic relevance in breast cancer remain unclear. By integrating genetic epidemiology, multiomics transcriptomics analyses, and AI‐assisted drug prediction, we aimed to clarify the biological and clinical significance of CFB in breast cancer. Results Mendelian randomization analysis suggested a potential causal association between circulating CFB levels and breast cancer risk (OR = 1.048, 95% CI: 1.018–1.078, p = 0.001). Single‐cell transcriptomic analysis identified cancer‐associated fibroblasts (CAFs) as the primary cellular source of CFB within the tumor microenvironment. High CFB expression was significantly associated with advanced clinical stage, lymph node metastasis, and poor overall survival and was confirmed as an independent prognostic factor (HR = 2.35, 95% CI: 1.55–3.56, p < 0.001). Tumors with elevated CFB displayed immunosuppressive characteristics, including increased regulatory T cells and M2 macrophages, higher TIDE scores, and strong correlations with immune checkpoint molecules. AI‐based drug sensitivity prediction and validation analyses revealed that CFB‐high tumors exhibited enhanced sensitivity to PARP inhibitors. Additional mutation‐related bioinformatic analyses showed that CFB‐mutated tumors were associated with higher TMB, increased MSI‐H proportion, an immunosuppressive microenvironment, and enhanced predicted sensitivity to PARP inhibitors. Mechanistically, CFB expression strongly correlated with PARP1 ( R = 0.77), and CAF‐derived CFB enhanced olaparib‐induced DNA damage in TNBC models. Conclusion Through integrative traditional and AI‐driven approaches, this study supports CFB as a genetically associated risk protein with potential causal relevance and as a prognostic and therapeutic biomarker at both the expression and mutation levels in breast cancer. These findings provide a mechanistic and translational basis for precision therapy targeting CFB‐overexpressing tumors.
Xiang et al. (Thu,) studied this question.